Article by unknown

* Says early stage diabetes drug meets trial goal

* Q4 loss/shr 55 cents vs est loss/shr 55 cents

* Shares up 7 pct

Aug 10 (Reuters) – Array BioPharma Inc (ARRY.O) said an early-stage trial of its experimental diabetes drug met the main goal of the study and that its quarterly loss was in line with market estimates.

The drug, codenamed ARRY-403, was tested in 41 patients with Type 2 diabetes, who received either single doses of the drug ranging from 25 mg to 400 mg, or a dummy drug.

The drug met its primary and secondary goals of safety, pharmacokinetics and glucose control, the company said.

Array, which focuses on cancer, inflammatory and metabolic diseases, said it was initiating a study in Type 2 diabetes patients to evaluate safety, exposure and glucose control of the drug over a 10-day period.

“Based on the pharmacokinetic and safety profile, coupled with effective glucose control, we believe ARRY-403 has the potential to be a first-line therapy with once-a-day dosing,” Chief Scientific Officer Kevin Koch said in a statement.

Type 2 diabetes occurs when the body loses its ability to use insulin to convert food to fuel. It is often linked with obesity, poor diet and lack of exercise.

In a separate statement, Array posted a fourth-quarter net loss of .7 million, or 55 cents a share, compared with a net loss of .4 million, or 68 cents a share, a year ago.

Total revenue fell 10 percent to .5 million.

The company also said that it discontinued the enrollment of new patients in the clinical trial of ARRY-797 in ankylosing spondylitis, but did not disclose other details.

Shares of the company rose 7 percent to .75 in after market trade. They closed at .45 Monday on Nasdaq. (Reporting by Esha Dey in Bangalore; Editing by Anil D’Silva) resd more>>

About the Author

unknown

Related posts:

1. FDA considers halting GSK drug Avandia safety trial FDA considers halting GSK drug Avandia safety trial The three-year debate about the safety of GlaxoSmithKline’s diabetes drug Avandia may be reaching a climax. Read more on...


2. Astra, BMS diabetes drug hits targets in new trial | Stock Market News Experimental drug dapagliflozin cut blood sugar in trial * Trial was of combination of new drug with glimepiride * If approved, dapagliflozin could be first SGLT2 inhibitor...


3. Lilly, MacroGenics Say Diabetes Treatment Misses Goal in Late-Stage Study   Diabetes Care: The latest News/Updates By David Olmos – Thu Oct 21 00:17:49 GMT 2010 Eli Lilly & Co. and MacroGenics Inc. said an experimental diabetes...


4. PharmaGossip: Roche Suspends Diabetes Drug Trial – WSJ.com ZURICH—Roche Holding AG has suspended late-stage trials of experimental diabetes drug taspoglutide due to side effects in another heavy blow to its medical pipeline, which is scheduled...


5. XE.com – UPDATE 2-Roche suspends dosing in diabetes drug trials Roche Holding has stopped giving patients its experimental diabetes treatment taspoglutide in late stage clinical trials due to a high rate of adverse reactions, marking a major...